NR3C2 and chronic kidney disease: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with mild to severe chronic kidney disease with increased albuminuria and type 2 diabetes.